List view / Grid view
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
11 May 2016 | By Victoria White, Digital Content Producer
A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II in a deal valued at up to €18 million...
11 May 2016 | By Victoria White, Digital Content Producer
Vekacia demonstrated efficacy and tolerability vs placebo in the treatment of active, severe vernal keratoconjunctivitis (VKC) in paediatric patients...
10 May 2016 | By Coulter Partners
Coulter Partners was delighted to partner once again with German / Dutch diagnostics company Curetis N.V...
10 May 2016 | By Jensen Lee, Logan Instruments Corp
Logan Instruments Corp. has diversified its portfolio through the expanding use of their Disso III-7 instrument...
10 May 2016 | By Victoria White, Digital Content Producer
RPL554 is a novel inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule...
10 May 2016 | By Victoria White, Digital Content Producer
Researchers have shown a modified dosage rtPA can reduce serious bleeding in the brain and improve survival rates in patients with acute stroke...
10 May 2016 | By Victoria White, Digital Content Producer
Takeda has received $38 million grant from the Bill & Melinda Gates Foundation to support global polio eradication in developing countries...
9 May 2016 | By L.B. Bohle Maschinen + Verfahren GmbH
The company’s history began with a blender in 1987 – in the meantime, L.B. Bohle, the machine builder from Ennigerloh, has manufactured more than 3,000 blenders...
9 May 2016 | By Victoria White, Digital Content Producer
The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialise Iclusig...
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
9 May 2016 | By Victoria White, Digital Content Producer
MGB Biopharma presented Phase I and preclinical data together with a proposal for the further development of oral MGB-BP-3 in C. difficile infections...
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
9 May 2016 | By Victoria White, Digital Content Producer
Allergan and Richter have announced positive results from Venus I, evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids...
6 May 2016 | By Victoria White, Digital Content Producer
Akili has started enrolment for its pivotal STARS-ADHD trial that will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO...
